Clinical trials
Acute Leukemia clinical trials
Below are recruiting acute leukemia clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07062250Recruiting
Home blood tests and transfusions for new AML patients
This trial tests whether people with newly diagnosed AML can safely check their own blood counts at home and receive transfusions there while getting chemotherapy at home. If it works, you may need fewer hospital visits.
CopenhagenAges 18 years+ - NCT01853631RecruitingPhase 1
CAR T-cell therapy for CD19-positive B-cell blood cancers
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
Houston, TexasAges Up to 75 years - NCT03932903Recruiting
Phone coaching to help teens stay on leukemia medicine
This trial tests a mobile (phone) health program to help adolescents and young adults with leukemia take their oral chemotherapy medicine consistently. It may help if staying on daily pills is hard during the maintenance phase of treatment.
Chicago, IllinoisAges 14 years+ - NCT07405424Recruiting
Spiritual care support for adults with new acute leukemia
This study tests whether adding spiritual care to standard treatment helps adults newly diagnosed with acute leukemia feel better emotionally and spiritually. You may join if you are starting your first hospital treatment for AML or ALL.
Chicago, IllinoisAges 18 years+ - NCT07470073RecruitingEarly Phase 1
Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Wuhan, HubeiAges 12–75 - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Tucson, ArizonaAges 18 years+ - NCT07044687RecruitingPhase 4
Venetoclax with azacitidine for newly diagnosed AML
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Gurgaon, HaryanaAges 18 years+ - NCT06874257Recruiting
Study of IDO1 inhibitor and PD-1 blocker for AML
This trial tests a combination of two drugs (an IDO1 inhibitor and a PD-1 blocker) given with standard chemotherapy (azacitidine and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The goal is to see if this approach helps the immune system fight the leukemia better.
BolognaAges 18 years+ - NCT06247501RecruitingPhase 2
CAR-T therapy for children with B-cell ALL needing transplant
This study tests a new type of immune-cell therapy (called CAR-T cells) for children and young adults with a specific blood cancer (B-cell ALL) who need a stem cell transplant. The treatment uses a patient's own T-cells that are modified to find and kill cancer cells with the CD19 marker.
SeoulAges Up to 25 years - NCT05317494Recruiting
Test of venetoclax for AML when intensive chemo isn’t possible
This study looks at how a person’s leukemia “disease state” changes over time for adults with acute myeloid leukemia (AML) who cannot receive the strongest (“intensive”) chemotherapy. It tests using oral venetoclax as a first treatment option, which may help control the disease for people ineligible for intensive chemo.
Pátrai, AchaiaAges 18 years+ - NCT07304011RecruitingPhase 2
Olutasidenib and azacitidine for IDH1-mutated AML after venetoclax
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
Sacramento, CaliforniaAges 18 years+ - NCT04167696RecruitingPhase 1
Dose-finding drug study for AML or MDS after standard options fail
This Phase 1 trial tests CYAD-02 to find the safest and recommended dose for people with AML or MDS that has returned or did not respond to prior treatment. It may help if you have limited treatment options, but participation also requires meeting specific heart, lung, and lab safety requirements.
Jacksonville, FloridaAges 18 years+ - NCT05029531RecruitingPhase 3
Immuno-chemotherapy for infants with B-lineage ALL
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
Moscow, Samory-Mashela,1Ages 1 day–12 months - NCT05054257RecruitingPhase 1
CAR T19 for hard-to-treat blood cancers that have CD19
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
PragueAges 18–80 - NCT05974150Recruiting
Remote symptom monitoring for several blood and cancer types
This study checks how well remote (at-home) symptom check-ins work for people with certain cancers. It may help patients and clinicians spot problems earlier and improve day-to-day care during treatment and beyond.
New Haven, ConnecticutAges 18 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Pembroke Pines, FloridaAges 18–59 - NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Duarte, CaliforniaAges 18 years+ - NCT06287229RecruitingPhase 1/Phase 2
CAR T therapy for B-cell ALL after initial treatment
This trial tests whether a special immune cell therapy (brexucabtagene autoleucel, or CAR T therapy) can help people with B-cell acute lymphocytic leukemia (ALL) after reducing the number of leukemia cells with a chemo-immunotherapy combination. It is for patients whose cancer has returned or is hard to treat, or for those newly diagnosed with a high-risk form of ALL.
Houston, TexasAges 18 years+ - NCT06561074RecruitingPhase 2
Study of calaspargase, decitabine, and venetoclax for young T-cell cancer
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
Houston, TexasAges 1 month–21 years - NCT07384715RecruitingPhase 1
GEN3018 for AML or high-risk MDS
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
AarhusAges 18 years+ - NCT05124288Recruiting
Study immune changes after AML relapse after bone marrow transplant
This study looks at how the immune system changes when acute myeloid leukemia (AML) comes back after a donor stem cell transplant. It may help researchers create more personalized treatment plans and future guidelines for how to care for people in this situation.
Milan, MilanoAges 18 years+ - NCT05587049Recruiting
Testing an oral medicine plus azacitidine to improve AML disease
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
Medellín, AntioquiaAges 18 years+ - NCT04049539RecruitingPhase 1/Phase 2
Vyxeos for AML that stays after initial chemotherapy
This trial tests whether Vyxeos (a type of chemotherapy) can treat acute myeloid leukemia (AML) that did not fully go away after standard induction (“7+3”) chemotherapy. It targets people whose leukemia is still present in the bone marrow and need a stronger “re-induction” treatment.
Sacramento, CaliforniaAges 18–75 - NCT05772559Recruiting
Study of AML genes and drug response in young patients
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
AmiensAges Up to 25 years
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute leukemia?
- Yes. Clin2 currently lists 942 recruiting acute leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.